Pregled bibliografske jedinice broj: 359100
Monoclonal antibodies in angiogenesis inhibition – Bevacizumab and Vitaxin to fight cancer
Monoclonal antibodies in angiogenesis inhibition – Bevacizumab and Vitaxin to fight cancer // Journal of EMSA on Medical and Scientific Affairs, 2007 (2007), 21-25 (podatak o recenziji nije dostupan, pregledni rad, znanstveni)
CROSBI ID: 359100 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Monoclonal antibodies in angiogenesis inhibition – Bevacizumab and Vitaxin to fight cancer
Autori
Kibel Aleksandar
Izvornik
Journal of EMSA on Medical and Scientific Affairs (0779-1577) 2007
(2007);
21-25
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
neovascularization; monoclonal antibodies; vascular endothelial growth factor A; integrins; cells; therapy
Sažetak
One of the possible ways to inhibit development of a tumor is blocking the growth of new blood vessels that provide oxygen and nutrients to the malignant cells. A new approach is to use the high specificity of monoclonal antibodies to target essential angiogenic molecules. These antibodies are derived from cell lines consisting of identical clones, and recognize the same part of a macromolecule. The most relevant are bevacizumab and vitaxin. The first one is approved for the first-line treatment of metastatic colorectal cancer, whereas vitaxin is still in clinical trials. Preliminary results are optimistic, and the drugs are generally well tolerated by the patients.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
